Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Gillian C. Ivers-Read net worth and biography

Gillian Ivers-Read Biography and Net Worth

Insider of Clovis Oncology

Gillian C. Ivers-Read is one of our co-founders and has served as our Executive Vice President and Chief Regulatory Officer since our inception. Previously, Ms. Ivers-Read served as Executive Vice President, Development Operations at Pharmion Corporation (acquired in 2008), beginning in 2002. From 1996 to 2001, Ms. Ivers-Read held various regulatory positions with Hoechst Marion Roussel and its successor, Aventis Pharmaceuticals, Inc., where she most recently held the position of Vice President, Global Regulatory Affairs. From 1994 to 1996, Ms. Ivers-Read was Vice President, Development and Regulatory Affairs for Argus Pharmaceuticals, and from 1984 to 1994, she served as a regulatory affairs director for Marion Merrell Dow. Ms. Ivers-Read received a B.Sc. in pharmacology from University College London.

What is Gillian C. Ivers-Read's net worth?: The estimated net worth of Gillian C. Ivers-Read is at least $0.00 as of May 4th, 2021. Ms. Ivers-Read owns 248,828 shares of Clovis Oncology stock worth more than $0 as of April 26th. This net worth evaluation does not reflect any other assets that Ms. Ivers-Read may own. Learn More about Gillian C. Ivers-Read's net worth.
How old is Gillian C. Ivers-Read?: Ms. Ivers-Read is currently 64 years old. There are 4 older executives and no younger executives at Clovis Oncology. Learn More on Gillian C. Ivers-Read's age.
How do I contact Gillian C. Ivers-Read?: The corporate mailing address for Ms. Ivers-Read and other Clovis Oncology executives is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. Clovis Oncology can also be reached via phone at 303-625-5000 and via email at [email protected]. Learn More on Gillian C. Ivers-Read's contact information.
Has Gillian C. Ivers-Read been buying or selling shares of Clovis Oncology?: Gillian C. Ivers-Read has not been actively trading shares of Clovis Oncology over the course of the past ninety days. Most recently, Gillian C. Ivers-Read sold 3,683 shares of the business's stock in a transaction on Tuesday, August 3rd. The shares were sold at an average price of $4.82, for a transaction totalling $17,752.06. Learn More on Gillian C. Ivers-Read's trading history.
Who are Clovis Oncology's active insiders?: Clovis Oncology's insider roster includes Paul Gross (Insider), Thomas Harding (Insider), Gillian Ivers-Read (Insider), and Lindsey Rolfe (Insider). Learn More on Clovis Oncology's active insiders.

Gillian C. Ivers-Read Insider Trading History at Clovis Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/3/2021	Sell	3,683	$4.82	$17,752.06
5/4/2021	Sell	3,952	$5.54	$21,894.08	248,828
2/2/2021	Sell	10,990	$7.97	$87,590.30
6/3/2020	Sell	598	$7.03	$4,203.94	207,720
3/20/2020	Sell	829	$4.60	$3,813.40	205,650
9/20/2019	Sell	837	$4.80	$4,017.60	194,346
9/4/2019	Sell	630	$5.21	$3,282.30	192,413
2/15/2018	Sell	3,000	$54.09	$162,270.00	180,571
1/16/2018	Sell	3,000	$59.16	$177,480.00	183,571
12/15/2017	Sell	3,000	$64.16	$192,480.00	182,583
11/15/2017	Sell	3,000	$63.70	$191,100.00
10/16/2017	Sell	3,000	$84.54	$253,620.00
9/15/2017	Sell	3,000	$69.50	$208,500.00	191,583
8/15/2017	Sell	3,000	$70.05	$210,150.00	194,583
7/17/2017	Sell	3,000	$91.56	$274,680.00	197,583
6/15/2017	Sell	3,000	$61.82	$185,460.00	200,583
5/15/2017	Sell	3,000	$47.39	$142,170.00	203,583
4/17/2017	Sell	3,000	$56.02	$168,060.00	206,583
3/15/2017	Sell	3,000	$66.99	$200,970.00	209,583
10/15/2015	Sell	3,000	$91.91	$275,730.00	212,583
9/18/2015	Sell	3,000	$112.56	$337,680.00	215,583

Gillian C. Ivers-Read Buying and Selling Activity at Clovis Oncology

Clovis Oncology Company Overview

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Today's Range

Now: N/A

50 Day Range

MA: $0.43

$0.08

$1.09

2 Week Range

Now: N/A

Volume

1,155,888 shs

Average Volume

8,875,886 shs

Market Capitalization

$11.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Claim Your Complimentary Bitcoin Reward

From Crypto Swap Profits | Ad

Secure Your Spot Now